MARLBOROUGH, Mass., May 15, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.
Mike Mahoney, chairman and chief executive officer, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. EDT. A live webcast of the session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com.
The replay of the webcast will be accessible at investors.bostonscientific.com beginning approximately one hour following the completion of each event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS | |
Media: | Investors: |
Kate Haranis | Lauren Tengler |
508-683-6585 (office) | 508-683-4479 (office) |
Media Relations | Investor Relations |
Boston Scientific Corporation | Boston Scientific Corporation |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$81.60 |
| Daily Change: | 0.23 0.28 |
| Daily Volume: | 3,035,508 |
| Market Cap: | US$119.950B |
May 18, 2024 | |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
